Evidence map›Paper›PMID 38902718›Full record

ArticleBMC cancer2024

Impact of mobile health technologies on human papillomavirus vaccination uptake among mothers of unvaccinated girls aged 9-14 years in Lagos, Nigeria (mHealth-HPVac): study protocol of a randomised controlled trial.

Kehinde S Okunade, Adebola A Adejimi, Temitope V Adekanye, Matthew J Allsop, Hameed Adelabu, Olufemi Thomas-Ogodo, Tonia C Onyeka, Teniola Lawanson, Godwin O Akaba, Omolola Salako and 2 more

Abstract readClinical Trial Protocol
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Kehinde S OkunadeDepartment of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos University Teaching Hospital, PMB 12003, Surulere, Lagos, Nigeria. sokunade@unilag.edu.ng.
Adebola A AdejimiDepartment of Community Health and Primary Care, College of Medicine, University of Lagos, Surulere, Lagos, Nigeria.
Temitope V AdekanyeDepartment of Obstetrics and Gynaecology, Lagos University Teaching Hospital, Surulere, Lagos, Nigeria.
Matthew J AllsopAcademic Unit of Palliative Care, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Hameed AdelabuCenter for Clinical Trials, Research, and Implementation Science, (CCTRIS), College of Medicine, University of Lagos, Surulere, Lagos, Nigeria.
Olufemi Thomas-OgodoDepartment of Obstetrics and Gynaecology, Lagos University Teaching Hospital, Surulere, Lagos, Nigeria.
Tonia C OnyekaDepartment of Anaesthesia, College of Medicine, University of Nigeria, Enugu, Enugu State, Nigeria.
Teniola LawansonCenter for Clinical Trials, Research, and Implementation Science, (CCTRIS), College of Medicine, University of Lagos, Surulere, Lagos, Nigeria.
Godwin O AkabaDepartment of Obstetrics and Gynaecology, College of Health Sciences, University of Abuja, Gwadalada, Abuja FCT, Nigeria.
Omolola SalakoDepartment of Radiation Biology, Radio-diagnosis and Radiography, College of Medicine, University of Lagos, Radiotherapy, Surulere, Lagos, Nigeria.
Rose I AnorluDepartment of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos University Teaching Hospital, PMB 12003, Surulere, Lagos, Nigeria.
Jonathan S BerekDepartment of Obstetrics and Gynaecology, Stanford University School of Medicine, Stanford, Palo Alto, CA, USA.

Funding

COMParative ASSessment of p16/Ki-67 DUal Staining Technology in women living with HIV (COMPASS-DUST study)K43TW011930 · FIC · COLLEGE OF MEDICINE, UNIVERSITY OF LAGOS · PI KEHINDE SHARAFADEEN OKUNADE · 2022 to 2026
$500k
Conquer Cancer Foundation 2024IIG-2761200216FIC NIH HHS K43 TW011930FIC NIH HHS K43TW011930
6 · The paper itself

Abstract

backgroundDespite the availability of effective vaccines, human papillomavirus (HPV) vaccine uptake remains low in most resource-limited settings including Nigeria. Mobile health technology (mHealth) has the potential to empower patients to manage their health, reduce health disparities, and enhance the uptake of HPV vaccination.

aimThe "mHealth-HPVac" study will assess the effects of mHealth using short text messages on the uptake of HPV vaccination among mothers of unvaccinated girls aged 9-14 years and also determine the factors influencing the uptake of HPV vaccination among these mothers.

methodsThis protocol highlights a randomised controlled trial involving women aged 25-65 years who will be enrolled on attendance for routine care at the General Outpatient clinics of Lagos University Teaching Hospital, Lagos, Nigeria between July and December 2024. At baseline, n = 123 women will be randomised to either a short text message or usual care (control) arm. The primary outcome is vaccination of the participant's school-age girl(s) at any time during the 6 months of follow-up. The associations between any two groups of continuous variables will be assessed using the independent sample t-test for normally distributed data, or the Mann-Whitney U test for skewed data. For two groups of categorical variables, the Chi-square (X2) test or Fisher's exact test will be used, as appropriate. Using the multivariable binary logistic regression model, we will examine the effects of all relevant sociodemographic and clinical variables on HPV vaccination uptake among mothers of unvaccinated but vaccine-eligible school-age girls. Statistical significance will be reported as P < 0.05. DISCUSSION: The mHealth-Cervix study will evaluate the impact of mobile technologies on HPV vaccination uptake among mothers of unvaccinated but vaccine-eligible school-age girls in Lagos, Nigeria as a way of contributing to the reduction in the wide disparities in cervical cancer incidence through primary prevention facilitated using health promotion to improve HPV vaccination uptake. REGISTRATION: PACTR202406727470443 (6th June 2024).

Indexed as

MothersPapillomavirus InfectionsPapillomavirus VaccinesTelemedicineVaccinationAdolescentAdultAgedChildFemaleHuman Papillomavirus VirusesHumansMiddle AgedNigeriaPatient Acceptance of Health CareRandomized Controlled Trials as TopicPapillomavirus VaccinesCervical cancerLagosMhealth-cervixNHISNigeriaPap test

Identifiers

PMID38902718
PMCPMC11191157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.